BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Drug Development

  Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses

  September 20, 2024

   · 

  8 min read
• Press Releases

  ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

  September 20, 2024

   · 

  2 min read
• Press Releases

  Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

  September 20, 2024

   · 

  6 min read
• Press Releases

  PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

  September 20, 2024

   · 

  2 min read
• Press Releases

  Metagenomi to Present at Chardan’s 8th Annual Genetic Medicines Conference

  September 20, 2024

   · 

  3 min read
• Press Releases

  Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

  September 20, 2024

   · 

  5 min read
• Press Releases

  RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer

  September 20, 2024

   · 

  34 min read
• FDA

  Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

  September 20, 2024

   · 

  2 min read
• News

  Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

  September 20, 2024

   · 

  20 min read
• Press Releases

  DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

  September 20, 2024

   · 

  10 min read